U. of Michigan will help investigate siRNA-based drugs.

Quark Pharmaceuticals and the University of Michigan Kresge Hearing Research Institute report that they will together conduct preclinical studies related to the treatment of acute hearing loss.

The collaborators will investigate siRNA compounds that inhibit Quark’s target genes for the prevention and treatment of acoustic trauma-induced acute hearing loss.

Quark reports that it expects to file an IND before the end of 2007 for its first hearing loss drug candidate, AHLi-11, for the prevention of cisplatin-induced ototoxic hearing loss.

Previous articlearGentis Signs On LifeCyte to Develop cGMP Facility
Next articleBaxter Completes Lyophilization Expansion